mProX™ Human STK38 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human STK38 Stable Cell Line (S01YF-1023-PY21). Click the button above to contact us or submit your feedback about this product.
Jordan Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jordan Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 In the ST486 cell line, STK38 kinase promotes anti-IgM-induced MYC downregulation and cell death.
Induction of STK38-WT and STK38-KD expression in the ST486 cell lines was achieved through doxycycline treatment, followed by subsequent crosslinking with anti-IgM antibody performed 24 hours after doxycycline induction. An additional 6-hour incubation of cells in the presence of anti-IgM was conducted, and apoptosis levels were assessed using the Annexin V binding assay via flow cytometry. The percentage of Annexin V positive cells was quantified, and P-values were determined through paired t-test analysis to evaluate the outcomes.
Ref: Bisikirska, Brygida C., et al. "STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma." Oncogene 32.45 (2013): 5283-5291.
Pubmed: 23178486
DOI: 10.1038/onc.2012.543
Research Highlights
Khan, Shahanshah. et al. "NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer." The Journal of clinical investigation, 2023.
Advanced stages of colorectal cancer (CRC) pose a formidable challenge, as they are seldom curable. Therefore, it is imperative to delve into the intricacies of CRC progression and invasion. Previous research had hinted at the tumor-suppressing role of NOD-like receptor family member NLRP12 in colorectal tumorigenesis, but the exact mechanisms remained elusive. This study uncovers that Nlrp12-deficient mice exhibit heightened invasive adenocarcinoma development, linked to increased expression of genes related to proliferation, matrix degradation, and epithelial-mesenchymal transition. Significantly, the Nlrp12-conditional knockout mice experiments unveil that NLRP12 effectively curtails β-catenin activation in intestinal epithelial cells, thus thwarting colorectal tumorigenesis. These findings spotlight NLRP12 as a potent antagonist of the Wnt/β-catenin pathway, with the NLRP12/STK38/GSK3β signaling axis emerging as a promising therapeutic avenue for CRC.
Khan, Shahanshah. et al. "NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer." The Journal of clinical investigation, 2023.
Pubmed:
37581937
DOI:
10.1172/JCI166295
Song, Runjie. et al. "A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer." Molecular cancer, 2023.
The treatment of Triple-negative breast cancer (TNBC) poses continuous challenges due to its heterogeneous nature and a lack of clearly defined molecular targets. This study, using publicly available RNA sequencing data from TNBC patients, aims to explore the impact of protein-coding circRNAs in the development and carcinogenesis of TNBC. The researchers identified multiple differentially expressed circRNAs associated with TNBC and suggest that further analysis of these molecules may offer novel perspectives for the understanding and treatment of TNBC.
Song, Runjie. et al. "A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer." Molecular cancer, 2023.
Pubmed:
37408008
DOI:
10.1186/s12943-023-01806-x
